Tirofiban

Names

[ Name ]:
Tirofiban

[Synonym ]:
Tirofiban [BAN:INN]
N-(Butylsulfonyl)-O-[4-(piperidin-4-yl)butyl]-L-tyrosine
N-(n-butanesulfonyl)-O-(4-(4-piperidinyl)butyl)-(S)-tyrosine
MFCD05237246
2-S-(n-Butylsulfonylamino)-3[4-(piperidin-4-yl)butyloxyphenyl]propionic acid
(S)-2-(butane-1-sulfonylamino)-3-[4-(4-piperidin-4-yl-butoxy)phenyl]-propionic acid
Agrastat
Agrastat (TN)
N-(Butylsulfonyl)-O-[4-(4-piperidinyl)butyl]tyrosine
(2S)-2-(butylsulfonylamino)-3-[4-(4-piperidin-4-ylbutoxy)phenyl]propanoic acid
UNII-GGX234SI5H
Aggrastat
Tirofiban
Tirofiban (INN)
Tyrosine, N-(butylsulfonyl)-O-[4-(4-piperidinyl)butyl]-
(2S)-2-(butane-1-sulfonamido)-3-{4-[4-(piperidin-4-yl)butoxy]phenyl}propanoic acid
N-(BUTYLSULFONYL)-O-[4-(4-PIPERIDINYL)BUTYL]-L-TYROSINE
L-tyrosine, N-(butylsulfonyl)-O-[4-(4-piperidinyl)butyl]-
L700462
MK383

Biological Activity

[Description]:

Tirofiban(L700462;MK383) is a potent non-peptide, glycoprotein IIb/IIIa (integrins alphaIIbbetaIII) antagonistTarget: integrin IIb/IIIa Tirofiban hydrochloride monohydrate blocks platelet aggregation and thrombus formation. Tirofiban is an antithrombotic used in the treatment of unstable angina.Tirofiban, in a concentration-dependent manner reduced platelet aggregation evoked by ADP (IC50 approximately 70 ng/ml), collagen (IC50 approximately 200 ng/ml), and thrombin (IC50 approximately 5,000 ng/ml).

[Related Catalog]:

Signaling Pathways >> Cytoskeleton >> Integrin

Research Areas >> Cardiovascular Disease

[References]

[1]. Winter JP, Juergens CP. The role of tirofiban in the management of coronary artery disease. Cardiovasc Hematol Disord Drug Targets. 2008 Jun;8(2):138-46.

[2]. van 't Hof AW, Valgimigli M. Defining the role of platelet glycoprotein receptor inhibitors in STEMI: focus on tirofiban. Drugs. 2009;69(1):85-100.

[3]. Valgimigli M, Biondi-Zoccai G, Tebaldi M et al. Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials. Eur Heart J. 2010 Jan;31(1):35-49.

[4]. Valgimigli M, Tebaldi M. Safety evaluation of tirofiban. Expert Opin Drug Saf. 2010 Sep;9(5):801-19.

[5]. Diaz JF, Cardenal R, Gomez-Manchero A, Sanchez-Gonzalez C. Safety and efficacy of tirofiban as adjunctive therapy for patients with ST-elevation myocardial infarction: a comparison versus placebo and abciximab. Cardiovasc Hematol Agents Med Chem. 2011 Jul 1;9(3):147-53.

[Related Small Molecules]

Chemical & Physical Properties

[ Density]:
1.2±0.1 g/cm3

[ Boiling Point ]:
611.7±65.0 °C at 760 mmHg

[ Melting Point ]:
223-225ºC

[ Molecular Formula ]:
C₂₂H₃₆N₂O₅S

[ Molecular Weight ]:
440.597

[ Flash Point ]:
323.7±34.3 °C

[ Exact Mass ]:
440.234497

[ PSA ]:
113.11000

[ LogP ]:
4.14

[ Vapour Pressure ]:
0.0±1.8 mmHg at 25°C

[ Index of Refraction ]:
1.532

[ Storage condition ]:
-20°C

Safety Information

[ Hazard Codes ]:
Xi

[ Risk Phrases ]:
36/37/38

[ Safety Phrases ]:
S22-S26-S30-S36/37/39-S45

[ RIDADR ]:
UN3261

[ Packaging Group ]:
II

[ Hazard Class ]:
8

[ HS Code ]:
2942000000

Synthetic Route

Click to get detail synthetic route

Precursor & DownStream

Precursor

DownStream

Customs

[ HS Code ]: 2942000000

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.